Over the last 7 days, the United States market has experienced a 1.4% drop, yet it remains up by 11% over the past year with earnings projected to grow by 14% annually. In such a dynamic environment, identifying high growth tech stocks requires evaluating their potential for innovation and scalability amidst these fluctuating market conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
| Ardelyx | 20.78% | 59.46% | ★★★★★★ |
| Travere Therapeutics | 26.41% | 64.47% | ★★★★★★ |
| Blueprint Medicines | 21.36% | 61.45% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.65% | 61.11% | ★★★★★★ |
| AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
| Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
| Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Bilibili (NasdaqGS:BILI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Bilibili Inc. offers online entertainment services targeted at young audiences in China, with a market capitalization of $7.78 billion.
Operations: Bilibili Inc. generates revenue primarily through mobile games, value-added services, advertising, and e-commerce. The company focuses on engaging the young demographic in China by offering a diverse range of online entertainment content.
Bilibili, a key contender in the interactive media and services sector, is navigating its path toward profitability with an expected earnings growth of 47.78% annually. Despite current unprofitability, the company's revenue trajectory is promising with an 8.6% annual increase, outpacing the general US market rate. Recent financial disclosures reveal substantial progress: Q1 sales surged to CNY 1.73 billion from CNY 982.81 million year-over-year, alongside a dramatic reduction in net loss to CNY 9.1 million from CNY 748.55 million, underscoring significant operational improvements and efficient cost management strategies.
- Dive into the specifics of Bilibili here with our thorough health report.
Evaluate Bilibili's historical performance by accessing our past performance report.
CoreWeave (NasdaqGS:CRWV)
Simply Wall St Growth Rating: ★★★★★☆
Overview: CoreWeave, Inc. operates a cloud platform focused on scaling, support, and acceleration for GenAI with a market cap of $51.54 billion.
Operations: The company generates revenue primarily from its data processing services, amounting to $2.71 billion.
CoreWeave has recently demonstrated a robust strategic approach to scaling its AI and cloud computing capabilities. With a notable 37.3% annual revenue growth, the company is outperforming the broader US market significantly. This growth trajectory is complemented by an aggressive expansion into European markets with a $2.2 billion investment aimed at enhancing AI cloud infrastructure, powered entirely by renewable energy sources. Moreover, CoreWeave's recent $4 billion deal with OpenAI to boost cloud computing capacity underscores its pivotal role in powering next-generation AI technologies, positioning it well for future industry demands despite its current unprofitability forecasted to pivot within three years with an expected earnings surge of 67.5% annually.
- Click here and access our complete health analysis report to understand the dynamics of CoreWeave.
Assess CoreWeave's past performance with our detailed historical performance reports.
Legend Biotech (NasdaqGS:LEGN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Legend Biotech Corporation is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of novel cell therapies for oncology and other indications across the United States, China, and Europe with a market cap of approximately $5.22 billion.
Operations: Legend Biotech focuses on developing and commercializing innovative cell therapies, generating revenue primarily from its biotechnology segment, which amounts to $728.30 million.
Amidst a dynamic biotech landscape, Legend Biotech is making notable strides with its innovative CAR-T therapies, as evidenced by recent data presentations at major oncology conferences. The company's aggressive R&D focus is highlighted by a significant increase in its research budget, aligning with its strategic expansion into solid tumor treatments. Despite a current unprofitable status, Legend Biotech's revenue surged to $195 million in Q1 2025 from $94 million the previous year, demonstrating a robust growth trajectory. This performance is underpinned by substantial investments in new facilities like their upcoming global headquarters in New Jersey, ensuring sustained growth and innovation in cutting-edge biotechnological research and therapies.
- Take a closer look at Legend Biotech's potential here in our health report.
Gain insights into Legend Biotech's past trends and performance with our Past report.
Next Steps
- Reveal the 237 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Legend Biotech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com